IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.882
AS - Asia 2.920
EU - Europa 1.831
SA - Sud America 416
AF - Africa 48
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.108
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.803
SG - Singapore 1.532
CN - Cina 436
IT - Italia 386
RU - Federazione Russa 360
BR - Brasile 338
HK - Hong Kong 332
VN - Vietnam 240
IE - Irlanda 238
DE - Germania 205
FR - Francia 131
GB - Regno Unito 108
JP - Giappone 107
FI - Finlandia 95
UA - Ucraina 72
IN - India 68
NL - Olanda 52
CA - Canada 45
ID - Indonesia 38
SE - Svezia 37
KR - Corea 34
PL - Polonia 31
AR - Argentina 29
AT - Austria 28
ES - Italia 27
CO - Colombia 18
MX - Messico 18
PK - Pakistan 16
TR - Turchia 16
ZA - Sudafrica 16
BD - Bangladesh 13
CH - Svizzera 12
IQ - Iraq 12
EC - Ecuador 9
MA - Marocco 9
MY - Malesia 9
PH - Filippine 9
PY - Paraguay 9
CL - Cile 8
LT - Lituania 7
PT - Portogallo 7
UZ - Uzbekistan 7
AU - Australia 6
BE - Belgio 6
RO - Romania 6
GR - Grecia 5
IR - Iran 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
JM - Giamaica 4
KE - Kenya 4
KZ - Kazakistan 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EG - Egitto 3
EU - Europa 3
IL - Israele 3
LB - Libano 3
MN - Mongolia 3
NP - Nepal 3
PA - Panama 3
SI - Slovenia 3
TH - Thailandia 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
ET - Etiopia 2
GE - Georgia 2
JO - Giordania 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CG - Congo 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
RE - Reunion 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 18.108
Salva come PNG Salva come JPEG
Città #
Wilmington 3.182
Houston 2.943
Woodbridge 1.607
Singapore 751
Fairfield 687
Ashburn 578
San Jose 369
Seattle 331
Hong Kong 328
Chandler 302
Cambridge 255
Dublin 219
Council Bluffs 208
Ann Arbor 191
Dallas 172
Beijing 158
The Dalles 158
Medford 152
Santa Clara 119
Tokyo 95
Dearborn 93
Rome 85
Ho Chi Minh City 80
Los Angeles 74
Lawrence 72
Munich 67
Hanoi 63
Lauterbourg 63
Moscow 58
San Diego 54
New York 52
Buffalo 50
Jacksonville 43
Helsinki 39
Redondo Beach 36
Lappeenranta 34
Nuremberg 33
Jakarta 31
Milan 31
São Paulo 30
London 29
Chennai 24
Del Norte 21
Zhengzhou 21
Orem 20
Seoul 20
Salt Lake City 19
Menlo Park 18
North Bergen 18
Boardman 17
Toronto 17
Perugia 16
Frankfurt am Main 15
Redwood City 15
Brooklyn 14
Chicago 14
Colorado Springs 14
Montreal 14
Vienna 14
Warsaw 14
Boston 13
Esslingen am Neckar 13
Hyderabad 13
Kraków 13
Shanghai 13
Atlanta 12
Johannesburg 12
Denver 11
Falls Church 10
Guangzhou 10
Manchester 10
Pune 9
Saint Petersburg 9
Turku 9
Amsterdam 8
Ankara 8
Da Nang 8
Haiphong 8
San Francisco 8
Stockholm 8
Asunción 7
Bologna 7
Engelhard 7
Phoenix 7
Poplar 7
Porto Alegre 7
Brussels 6
Columbus 6
Goiânia 6
Guiyang 6
Kilburn 6
Lahore 6
Mexico City 6
Montjovet 6
Norwalk 6
Rio de Janeiro 6
Turin 6
Zurich 6
Belo Horizonte 5
Bogotá 5
Totale 14.576
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 529
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 436
Brodalumab for the treatment of psoriasis 429
Tildrakizumab for treating psoriasis 421
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 418
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 406
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 400
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 395
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 394
Tofacitinib for the treatment of psoriasis 394
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 391
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 369
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 366
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 366
A safety evaluation of guselkumab for the treatment of psoriasis 361
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 347
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 345
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 340
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 338
Photo-recall cutaneous reaction to gemcitabine 318
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 318
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 309
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 300
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 295
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 288
Pharmacotherapeutic management of psoriasis in adolescents and children 267
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 265
Skin immunity and its dysregulation in psoriasis 257
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 253
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 251
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 245
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 242
Successful treatment of psoriatic crumbly nails with ustekinumab 239
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 222
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 220
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 216
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 200
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 197
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 193
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 193
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 152
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 138
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 134
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 132
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 128
Italian guidelines in diagnosis and treatment of alopecia areata 123
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 121
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 116
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 112
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 110
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 109
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 105
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 105
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 103
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 101
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 98
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 96
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 93
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 91
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 90
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 88
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 88
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 86
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 85
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 85
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 85
Linear psoriasis following the typical distribution of the sciatic nerve 81
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 81
Quality of life and psychological impact in patients with atopic dermatitis 81
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 80
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 78
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 78
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 77
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 76
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 74
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 74
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 74
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 73
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 72
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 71
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 71
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 70
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 70
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 68
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 67
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 66
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 66
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 65
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 64
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 63
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 62
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 61
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 61
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 60
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 58
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 58
Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor 58
Eczematous liraglutide eruption managed by dupilumab: A case report 58
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 57
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 57
Totale 17.837
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.230
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.230
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021265 0 0 0 0 0 0 0 0 0 161 75 29
2021/2022861 46 69 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20263.881 293 158 578 254 359 152 627 526 552 382 0 0
Totale 18.793